- FDA approves Merck's Gardasil for prevention of anal cancer
- FDA advisory committee recommends expanded use of Gardasil
- MinuteClinic to offer vitamin B12 injections, HPV vaccination
- Adherence among chronic disease patients can lead to big savings
- Walgreens puts its money where its mouth is with World AIDS Day campaign
WHITEHOUSE STATION, N.J. — Merck’s vaccine for human papillomavirus is 89% effective in preventing genital warts in teenage boys and young men, according to a new study.
The phase-3 study of Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 and 18] vaccine, recombinant) in boys and men ages 16 to 26 years was published in the Feb. 3 issue of the New England Journal of Medicine. Human papillomavirus is the cause of genital and anal warts, and infection can increase the risk of developing cancer later in life.
The Food and Drug Administration approved the vaccine for preventing anal cancer in males and females ages 9 to 26 years in December 2010, based on part of this study.